Literature DB >> 7850812

Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.

J Bartkova1, J Lukas, H Müller, M Strauss, B Gusterson, J Bartek.   

Abstract

D-type cyclins are proto-oncogenic cell cycle regulators implicated in the pathogenesis of several types of cancer. Amplification of the cyclin D1 gene has been described in 30-50% of human head and neck squamous cell carcinoma (HNSCC). Using immunohistochemistry on archival specimens of human HNSCC and a mAb DCS-6, which is specific for cyclin D1, strong positivity was found in nuclei of 9 (17%) of 52, a moderately elevated signal in 16 (31%) of 52, and weak staining comparable with normal tissues in 27 (52%) of 52 patients. Immunoblotting analysis of five HNSCC-derived cell lines showed three distinct spectra of D-type cyclin proteins: cyclin D1 only (in UMSCC-2 and UMSCC-22b cell lines with 11q13 amplification), cyclins D1 and D3 (in HN5 and HN6), or cyclins D1, D2, and D3 (in UMSCC-1). Electroporation of neutralizing antibodies demonstrated requirement for cyclin D1 in cell cycle progression of all five HNSCC cell lines. Cyclin D2 was essential and showed a cooperative effect with cyclin D1 in positive regulation of G1 in UMSCC-1 cells. These data are consistent with the proposed oncogenic role of cyclin D1 in HNSCC and open up the way for immunohistochemical assessment of cyclin D1 aberrations in archival clinical specimens. It is also suggested that excessive levels of cyclin D1 alone or cooperative effects of several D-type cyclin proteins may lead to deregulation of G1 control in distinct subsets of human HNSCC. These results are discussed in the context of possible functional redundancy of D-type cyclins and the role of the D-type cyclin/p16-CDKN2/pRB pathway in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850812

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  An alternative lifestyle for immortalized oral keratinocytes.

Authors:  R R Reddel
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

Review 3.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

4.  The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines.

Authors:  Jason S White; Joel L Weissfeld; Camille C R Ragin; Karen M Rossie; Christa Lese Martin; Michele Shuster; Chandramohan S Ishwad; John C Law; Eugene N Myers; Jonas T Johnson; Susanne M Gollin
Journal:  Oral Oncol       Date:  2006-11-16       Impact factor: 5.337

5.  Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.

Authors:  Wen-Liang Kuo; Jing Liu; Helena Mauceri; Everett E Vokes; Ralph Weichselbaum; Marsha Rich Rosner; Ezra Eddy Wyssam Cohen
Journal:  Mol Cancer Ther       Date:  2010-09-28       Impact factor: 6.261

6.  A mouse model of human oral-esophageal cancer.

Authors:  Oliver G Opitz; Hideki Harada; Yasir Suliman; Ben Rhoades; Norman E Sharpless; Ralph Kent; Levy Kopelovich; Hiroshi Nakagawa; Anil K Rustgi
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

8.  Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ β-catenin pathway.

Authors:  Pandurangan Ashokkumar; Ganapasam Sudhandiran
Journal:  Invest New Drugs       Date:  2009-12-15       Impact factor: 3.850

9.  Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer.

Authors:  Meili Hao; Xiangmei Chen; Ting Zhang; Tao Shen; Qing Xie; Xiujuan Xing; Hongxi Gu; Fengmin Lu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

Review 10.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.